Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LN-144 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LN-144 | Lifileucel | LN-144 (Lifileucel) is a preparation of tumor infiltrating lymphocytes isolated and expanded from patient tumor tissue, which may demonstrate enhanced anti-tumor immune activity when re-introduced into patients (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 3045-3045). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | melanoma | not applicable | LN-144 | Phase II | Actionable | In a Phase II trial, LN-144 treatment resulted in an objective response rate of 33% (3/9, 1 complete response, 2 partial response) in patients with advanced metastatic melanoma (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 3045-3045; NCT02360579). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02360579 | Phase II | LN-144 | Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144) | Active, not recruiting | USA | 7 |